In this New York Times commentary on Jan 13, Wafaa El- Sadr, MD, MPH, MPA, global director of ICAP, and co-authors – James Krellenstein and Peter Staley, the co-founders of PrEP4All, an activist think tank dedicated to increasing access to H.I.V. and Covid-19 treatments – call for the incoming US administration to create a new entity called the President’s Emergency Plan for Vaccine Access and Relief, or PEPVAR. This new entity – based on the model of PEPFAR, which has been effective in the global HIV response – would work rapidly to build facilities to manufacture vaccines and their constituent components at scale with the goal of supporting the production of enough doses to vaccinate the entire world within a year and providing countries with the resources needed to distribute and deliver the vaccines.
Read the full article in The New York Times.
Read the latest ICAP updates on COVID-19 here
A major global health organization that has been improving public health in countries around the world for over 15 years, ICAP works to transform the health of populations through innovation, science, and global collaboration. Based at Columbia University in New York City, where it is part of the Mailman School of Public Health, ICAP has projects in more than 30 countries, working side-by-side with ministries of health and local partners to confront some of the world’s toughest health challenges. Through meaningful research, tailored technical assistance, effective training and education programs, and rigorous surveillance to measure and evaluate the impact of public health interventions, ICAP aims to realize a global vision of healthy people, empowered communities, and thriving societies. Online at icap.columbia.edu